 |
|
| ADVANCES IN ANTIVIRAL DRUG DESIGN, VOLUME 4
| |
| | |
|
|
 To order this title, and for more information, click here
Edited By
E. De Clercq, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Included in series
Advances in Antiviral Drug Design, 4
Description
The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral
drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.
First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed
by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some
of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.
Second, high
expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle
of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.
Third, as all currently available PIs can be described as "peptidomimetic",
and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how
a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.
Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route)
have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as
they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses
as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.
Fifth, while the major current
efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis
C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J.
Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus
agents.
Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides
inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides,
an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.
The six topics covered
in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and
development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens
of current times: HIV, HBV, influenza virus and herpesviruses.
Contents
List of contributors. Preface. New anti-HIV agents in preclinical or clinical development (E. De Clercq). Inhibitors of human immunodeficiency
virus integration (D.J. Hazuda, S.D. Young). Non-peptidic protease inhibitors (NPPIs): Tipranavir (D. Mayers et al.). Design
of neuraminidase inhibitors as anti-influenza virus agents (H. Jin, C.U. Kim). Six-membered carbocyclic nucleosides (J. Wang, M. Froeyen,
P. Herdewijn). cycloSal-pronucleotides - Design of the concept, chemistry and antiviral activity (C. Meier). Index.
| Bibliographic details |
Hardbound, 230 pages, publication date: DEC-2003
ISBN-13: 978-0-444-50602-3
ISBN-10: 0-444-50602-0
Imprint: ELSEVIER
|
| Price and Ordering |
Price:
USD 128
GBP 75
EUR 110
|  |
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
|
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
|
092/943
Last update: 27 Sep 2008
|
|
| |
| | |
|
|
| |
